ActualMeds is a technology company.
ActualMeds is a technology company.
ActualMeds has raised $400K across 1 funding round.
ActualMeds has raised $400K in total across 1 funding round.
ActualMeds has raised $400K in total across 1 funding round.
ActualMeds's investors include Connecticut Innovations.
ActualMeds is a health care technology company specializing in automated clinical best practices for comprehensive medication review and reconciliation, serving high-risk patients across non-acute care settings.[1][2][8] Its core product, the InConcert Medication Management™ (ICMM) platform, combines AI, predictive analytics, process automation, and high-touch clinical pharmacist services to deliver patient-centered medication management, targeting payers, providers, skilled nursing facilities (SNFs), and chronic disease populations.[2][3][6] The platform solves critical problems like medication errors, polypharmacy, care gaps at transitions, and readmissions by harmonizing data from disparate sources, generating action plans, and enabling scalable outreach—serving over 200,000 patients across 41 states with proven results, including 17% reduction in SNF readmissions and $1.4M in annual avoidable costs for a 100,000-member health plan.[2][3]
ActualMeds has operated for over 14 years, pioneering automated solutions for medication management in post-acute care, evolving from a technology-focused firm into a hybrid service organization that prioritizes human needs alongside tech.[1][3][5] Its roots lie in deep expertise in data standards, interoperability (e.g., SNOMED), and participation in groups like the Pharmacy Quality Alliance (PQA), American Society of Consultant Pharmacists, and CMS study groups.[1] A pivotal evolution came from recognizing technology's limits, leading to "high-touch" strategies blending AI-driven automation with expert pharmacists; recent launches, like the 2023 medication reconciliation solution for LTC facilities to meet CMS MDS updates, highlight ongoing adaptation to regulatory changes.[5]
ActualMeds rides the wave of value-based care and digital health interoperability trends, addressing medication management gaps amid rising chronic diseases, post-acute transitions, and regulatory pressures like CMS MDS/PDPM reimbursement changes.[3][5][6] Timing aligns with AI adoption in healthcare for predictive analytics and automation, reducing labor-intensive processes in fragmented non-acute settings (e.g., SNFs, IDNs, ACOs).[2][4][7] Market forces favoring it include SNF staffing shortages, readmission penalties, and payer demands for cost-effective outcomes; by influencing standards via PQA/CMS and enabling scalable high-touch care, it bridges tech with clinical expertise, improving ecosystem efficiency and patient safety.[1][3]
ActualMeds is poised for expansion by leveraging ICMM's integrations and AI to capture more SNF/payer contracts amid tightening CMS rules and chronic care demands.[3][5] Trends like advanced AI for personalized regimens, broader EHR interoperability, and tele-pharmacy will amplify its scalability, potentially growing beyond 200k patients.[2][7] Its influence may evolve toward leading medication AI standards, further reducing national readmission rates and costs, solidifying its decade-long role as a patient-safety innovator in tech-enabled services.[1][4]
ActualMeds has raised $400K across 1 funding round. Most recently, it raised $400K Seed in May 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2014 | $400K Seed | Connecticut Innovations |